INTRODUCTION {#sec1-1}
============

Over the past decade, a transformation has swept across the U.S. healthcare system. Delivering patient-centered care and improving resource utilization have become 'mission critical' goals for healthcare providers. After promising during his election campaign to make U.S. health care reform a top priority, Barack Obama became the 44^th^ U.S. President in 2009. The following year, President Obama signed the *Patient Protection and Affordable Care Act* into law. Often referred to as *'Obamacare,'* this act set the stage for an even greater transformation of the U.S. healthcare landscape by creating a new paradigm for providers' delivery of healthcare with a focus shift from volume to value. As a result of these factors, interest in the practice of evidence-based medicine (EBM) in the U.S. has never been stronger.

With this increased interest in EBM and associated evidence-based laboratory medicine (EBLM) efforts, clinical societies, professional organizations and governmental groups have developed a greater awareness on the importance of clinical practice guidelines as well as the methods used for their development. In 2011, the Institute of Medicine (IOM) published two relevant reports: *'Clinical Practice Guidelines We Can Trust'* ([@ref1]) and *'Finding What Works in Health Care* -- *Standards for Systematic Reviews'* ([@ref2]). Promulgating these reports was part of the IOM's response to a legislative mandate from Congress requesting that steps be taken to implement recommendations from an earlier IOM report on *'Knowing What Works in Health Care (2008)'* ([@ref3]). As a result, the Department of Health and Human Services was commissioned to develop evidence-based, methodological standards for systematic reviews (SRs) and clinical practice guidelines (CPGs) ([@ref1]). These events also provided new resources for the National Academy of Clinical Biochemistry (NACB) at a time when it had become the 'Academy of AACC' and was reassessing their processes for development of laboratory medicine practice guidelines (LMPGs).

A brief history of NACB and a key program of the Academy -- Laboratory Medicine Practice Guidelines {#sec2-1}
---------------------------------------------------------------------------------------------------

The NACB was founded by a group of members from the Chicago Section of the American Association for Clinical Chemistry (AACC) in 1976. This core group of clinical chemists envisioned a learned professional society of doctoral level scientists employed in academic, research and/or hospital-based settings. Throughout its history, the scope, visibility and impact of the Academy's programs have grown steadily. Early on, two key Academy programs were a specific NACB Annual Meeting and the *Journal of Clinical Biochemistry.* In the 1990's, the overlap of individuals who held leadership positions in both AACC and NACB began to increase. Additionally, recognition of the benefits in synergistic collaboration across multiple programs and venues led to formal agreements between NACB and AACC, and were established in the spirit of working together more closely. The mission of NACB is to *'advance clinical practice and research and to promote education and professional development in clinical laboratory medicine'.* In 2006, AACC and NACB leaders signed an agreement to merge, expanding NACB's mission to include *'serving as the Academy of AACC'*.

One of the NACB's most visible programmatic initiatives continues to be the staging of conferences and symposia focusing on important topics in the disciplines of clinical biochemistry and laboratory medicine. In the mid-1990's, NACB leaders decided to replace the scientific symposia at their annual meetings with conferences aimed at *Standards of Laboratory Practice* (SOLPs). The model for this new format was a small meeting, often a satellite of the larger AACC conference, for which the proceedings and issues discussed would be published in the form of a monograph. These NACB monographs were early versions of clinical laboratory practice guidelines. Once published, they allowed for broader dissemination of conference findings and education of laboratory professionals. In 1999, NACB leaders decided to use a new name for future SOLPs, *Laboratory Medicine Practice Guidelines* (LMPGs). Since 1994, the NACB has developed, or is currently developing, nearly 20 SOLPs and LMPGs. A list of these documents is provided in [Table 1](#table001){ref-type="table"}.

Earlier SOLP's and LMPG's of the Academy are now either out of print or archived.

Today, LMPGs are documented practice recommendations resulting from evidence-based approaches to addressing questions regarding appropriate use of diagnostic laboratory testing in a specific scientific and/or clinical discipline. LMPGs are intended to improve the use of diagnostic laboratory tests in a manner that optimizes patient care outcomes and are based on practice recommendations informed by systematic review of the evidence. LMPGs include recommendations based on weighting and grading the relevant evidence. LMPGs also address the benefits and harms of alternative laboratory testing strategies. A key component of SOLPs and LMPGs has always been development in collaboration with other relevant clinical societies, stakeholders and/or professional organizations.

Sustaining guideline quality through standard operating procedures {#sec2-2}
------------------------------------------------------------------

Not long after the first SOLP was published, NACB leaders recognized that a long-term approach for ensuring the quality and impact of their guidelines would best be served by the development of policies or procedures for guideline development. This recognition led to a decision made by the NACB's Board of Director's (BOD) to include in their own manual a policy on LMPGs that also required the creation, use, and periodic revision of a Standard Operating Procedures (SOP) instrument for NACB Guideline Development Groups (GDGs) ([@ref4]). The first NACB SOLP SOP was created in 1997. Prior to the 2005 approval of the SOP by NACB's BOD, it had already been revised twice during the 8 years since the initial SOP was created.

Initially, responsibility for oversight of the development of LMPGs rested with the NACB's Education and Scientific Affairs Committee (ESAC). In 2009, AACC and NACB leaders decided that activities of AACC's EBM Committee should integrate more closely with programs of the Academy. By that time, the Committee had capably demonstrated a strong track record in offering programs and products as well as establishing a solid working relationship with the Agency for Healthcare Research and Quality (AHRQ) in the U.S. AHRQ is a government agency, part of the Department of Health and Human Services, that functions to support research to improve the quality of health care ([@ref5]).

Key members of AACC's EBM Committee continue their contributions to the field that contribute to maintaining EBM and EBLM at the forefront of numerous AACC and NACB initiatives ([@ref6],[@ref7]). In 2010, a new Evidence-Based Laboratory Medicine Committee (EBLMC) was formed combining the activities of AACC's EBM Committee and NACB's ESAC.

The EBLMC was charged with several responsibilities including oversight of LMPG development. The EBLMC is also charged with promoting and/or overseeing the collaborative efforts required in review and approval of other society or organizational guidelines for potential AACC endorsement. In fact, all NACB guideline development groups must have a member of the EBLMC who is selected through collaborative discussion between the LMPG committee chair and the EBLMC chair.

Given these roles, it made sense that the EBLMC would also take on the responsibility for ensuring that revisions of the LMPG SOP remained consistent with current best practices in clinical practice guideline development. Through an extended process that began in 2011 that involved multiple stages of review by key stakeholder groups in AACC and its Academy, the 2014 revision of the LMPG SOP was approved and is available to AACC and/or NACB members on NACB's webpage on the AACC website ([@ref8]). Before final AACC and NACB BOD approval, a draft of the 2014 LMPG SOP was posted allowing for and inviting open public comment on the proposed content in order to achieve openness and transparency of EBLMC's efforts to arrive at a final revision that could be widely utilized.

Content in the 2014 SOP was influenced significantly by the 2011 IOM report as well as by other available guideline development resources ([@ref9],[@ref10]). AACC and NACB leaders as well as members of the EBLMC recognized, acknowledged, and underscored the importance of developing LMPGs in a process consistent with the below key principles articulated in the 2011 IOM report on developing trustworthy clinical practice guidelines: Establishing transparencyManagement of conflict of interest (COI)Guideline development group compositionClinical practice guideline-systematic review intersectionEstablishing evidence foundations for and rating strength of recommendationsArticulation of recommendationsExternal reviewUpdating

LMPG committees are strongly encouraged to keep all elements of these standards in mind during the guideline development process and incorporate specifics, where applicable, in the final LMPG.

Components in the AACC organizational structure associated with guideline development, review and approval are numerous and varied. As a result, the nature of interactions and responsibilities between these components as well as with external groups, when applicable, are complex. Consequently, the importance and benefits of using the SOP as a mandatory guide by LMPG committees in LMPG development should be apparent. Organizational elements that can potentially be involved with the development of LMPGs and the use of the LMPG SOP as well as the activities related to review/approval of other external society or organizational guidelines are shown in [Figure 1](#fig001){ref-type="fig"}.

Shouldering the bulk of responsibility for the tremendous amount of work required for LMPG development is the LMPG committee itself. Several other groups have typically played a key role in the overall process including the EBLMC, AACC and NACB BODs as well as conference or meeting organizing groups such as the AACC's annual meeting organizing committees. LMPG committees are expected to be multidisciplinary and typically have members from other relevant clinical societies or professional organizations.

With the understanding that LMPGs are more likely to be utilized fully by both laboratorians and clinicians with the endorsement and support of the appropriate clinical society, LMPG Committees are strongly encouraged by the SOP to include clinical society members and to sign a collaborative Co-Sponsorship Agreement with the clinical society(s) involved.

The most important role on the LMPG committee is that of the LMPG chair. This individual, or individuals if there are co-chairs, may often be a key and active participant in one or more of AACC's Divisions that are unique groups or 'communities' that AACC members may join that focus on their specific area(s) of interest or expertise within the field of laboratory medicine. Presently, there are 18 scientific divisions within AACC.

Other LMPG development issues addressed in the 2014 SOP are the roles and responsibilities of all key stakeholder groups or individuals, how LMPG topics are selected, how to conduct the systematic review of the evidence (including selected examples of past and current data abstraction forms for this review) and how to evaluate the strength as well as grading of the final evidence-based recommendations. Significant ancillary activities required for LMPG development are also addressed. This category of information includes public presentation of LMPG information in selected program categories or venues, public posting of LMPGs including digital media, processes for guideline finalization and approval, requirements for LMPG publication, expected LMPG development timelines and requirements of a plan for future updating of the LMPG. This last item has not been well addressed in past versions of the SOP. In turn, being able to update key LMPGs when the 5 year active period has expired has, in the past, often been a challenge for NACB, ESAC and now, also the EBLMC.

Being able to assess the effectiveness of an LMPG is another area that has been lacking previously and is in keeping with the current SOP. Any initial proposal of a LMPG topic now takes into account such issues as target audience, guideline promotion and optimal utility and priority gaps that should be addressed. In addition, LMPG Committee selection focuses on bringing the appropriate partners to the table to facilitate the production of effective guidelines.

Critical issues to address for achieving best practices in guideline development {#sec2-3}
--------------------------------------------------------------------------------

Working collaboratively with other clinical societies and organizations remains a top priority in LMPG development. For more than two decades, this collaboration has involved close to 100 other clinical societies and/or professional organizations. Frequent partners include the College of American Pathologists, the Endocrine Society, the U.S. Centers for Disease Control and Prevention as well as the AHRQ. Now, with the emphasis being placed on clinical society collaboration on LMPGs, partnership organizations are increasing in number and variety. Current LMPGs in development involve collaboration with the American Academy of Pain Management, the American Congress of Obstetrics and Gynecology and other clinical groups.

Grading the quality of the evidence and the strength of recommendations also presents a challenge given the lack of systems effectively designed for use with diagnostic tests ([@ref11]). For grading the evidence and assigning the strength of recommendations LMPG committees, especially if the LMPG is developed in collaboration with leading clinical societies, use those systems that are routinely employed by the relevant clinical societies in their guideline development process. When this has not been the case, the system that has often been used by LMPG committees was an adapted and modified version from the U.S. Preventive Services Task Force Recommendations for Preventive Services ([@ref12]).

LMPGs have been typically posted on AHRQ's National Guideline Clearinghouse website for the five year active period per AHRQ policy ([@ref13]). As of early 2015, three LMPGs remain actively listed. One of these LMPGs on *'Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus'* also reported development of a new system designed by the LMPG committee for grading evidence and assigning the strength of recommendations ([@ref14],[@ref15]). This system also incorporates a new and specific expert-based consensus recommendation known as 'Best Practice Points.' The overall system reported and used by this LMPG committee will be an option for future guideline development groups, including LMPG committees, to consider since it was specifically designed for a guideline focusing on diagnostic testing.

Continuing to strive towards achieving best practices in guideline development and being able to sustain a greater level of consistency in LMPG development are emphasized in the 2014 SOP. That this would be a significant opportunity for improvement is not surprising considering the length of time since NACB groups first began developing SOLPs and, presently, AACC's Academy developing LMPGs in collaboration with an extensive number of partner societies.

The EBLMC and NACB leaders have underscored the importance of addressing and resolving these issues ([@ref16]). In 2011, the EBLMC decided that the guideline evaluation tool to be used by LMPG committees for this purpose should be the second edition of the AGREE (Appraisal of Guidelines for Research and Evaluation) instrument ([@ref17]). Use of the AGREE II instrument to evaluate the methodological quality of clinical practice guidelines has been reported ([@ref18]).

Another group reported using the AGREE II instrument to evaluate eleven NACB LMPGs (most now archived). This group found that five of eleven LMPGs had overall scores ≥ 50%.

However, while all provided useful information seen as applicable to clinical practice by the evaluators, there was still a wide variability in AGREE II domain scores ([@ref19]). Notably, the one guideline published ([@ref15]) after the development of the AGREE II instrument achieved a very high score ([@ref19]). To further advance the necessary support by EBLMC in LMPG or external society guideline review, the 2014 SOP describes a significant change made by EBLMC compared to previous methods of 'linking' the LMPG developing groups and those helping to oversee the development process. Historically, NACB required guideline chairs to be members of the Education and Scientific Affairs Committee. As noted previously, the practice now required in the 2014 SOP is for at least one EBLMC member, preferably with relevant content expertise and experience, to also serve on each new LMPG committee. In this manner, representative EBLMC members will be able to provide updates to the EBLMC on the progress and challenges experienced by the respective LMPG committees. Reciprocally, given that the EBLMC includes members with experience in guideline development and methodology, efforts are under way to make this expertise more available to LMPG committees.

CONCLUSION {#sec1-2}
==========

For all clinical guideline development groups, effective application of evidence-based laboratory medicine will continue to require openness and transparency as well as adaptability in their procedures and activities in the future.

For the EBLMC and future LMPG committees, significant opportunities remain for identifying ways that can increase the effectiveness of LMPGs, provide measurable indicators of their impact and document related changes in clinical practice associated with the new evidence-based recommendations regarding use of diagnostic tests. Indeed, employment of new communication strategies including digital media may prove useful to promote LMPG activities and evidence-based laboratory medicine.

Presently, there are three LMPG committees two focusing on new LMPG topics and one being an update of the widely recognized 2007 LMPG on Biomarkers of Cardiac Disease ([@ref20],[@ref21]). The LMPG committee for the latter is being formed, in part, from members of AACC's Biomarkers of Acute Cardiac Disease Division. This committee will undoubtedly include key members from other clinical societies in the cardiac disease and/or cardiology disciplines. It is anticipated that the next LMPG to be finalized from these three LMPG committees will be on the laboratory aspects of Pain Management and another one is under development on the clinical use of hCG testing.

All three of the current LMPGs in some stage of development include working with, and involving individuals from other clinical societies under the auspices of the EBLMC using the procedures contained in the 2014 SOP. The efforts will include the monitoring of the methodological quality of LMPGs by application of the AGREE II instrument.

Within the EBLMC as well as the leaders of NACB and the AACC, there is a strong, sustained commitment to ensure that the LMPG development process will continue to evolve and improve over time. This commitment must include the EBLMC and other groups remaining open to making future revisions to the 2014 SOP when necessary. For as so many individuals have stated in a quote, known widely: "if you're not getting better, you're getting worse."

![Promoting development of LMPGs and CPGs by the AACC Academy and EBLMC](ejifcc-26-158-g001){#fig001}

###### 

The year, topic and status of the SOLPs and LMPGs of the AACC Academy (the NACB)

  Year               Topic                                                                                                               Status
  ------------------ ------------------------------------------------------------------------------------------------------------------- --------------------------------
  1994               Nutritional Status                                                                                                  (Out of Print)
  1996               Diagnosis of Thyroid Disease                                                                                        **-**
  1998               Evaluation and Management of Newborns                                                                               (Out of Print)
  1999               Therapeutic drug Monitoring                                                                                         (Out of Print)
  1999               Cardiac Markers                                                                                                     (Archived)
  2000               Hepatic Injury                                                                                                      (Archived)
  2000               Electronic Medical Records                                                                                          **-**
  2002               Thyroid Disease                                                                                                     (Archived)
  2002               Diabetes Mellitus                                                                                                   (Archived)
  2003               Tumor Markers in the Clinic                                                                                         (Archived)
  2005               Emergency Toxicology                                                                                                (Archived)
  2006               Maternal-Fetal Risk Assessment                                                                                      (Archived)
  2007               Point of Care Testing                                                                                               (Archived)
  2007               Biomarkers of Acute Coronary Syndrome                                                                               (Published)
  2008               Expanded Newborn Screening                                                                                          (Published)
  2009               Emerging CV Risk Factors                                                                                            (Published)
  2009               Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers                                      (Published)
  2009               Use of Tumor Markers in Clinical Practice: Quality Requirements                                                     (Published)
  2010               Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers                                                      (Published)
  2010               Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice                                        (Published)
  2011               Diagnosis and Management of Diabetes Mellitus                                                                       (Published)
  (In development)   Pain Management                                                                                                     (Final title to be determined)
  (In development)   Biomarkers of Cardiac Disease                                                                                       (Final title to be determined)
  (In development)   Guidelines and Recommendations for Laboratory Analysis of Human Chorionic Gonadotropin (hCG) in Clinical Practice   (Final title to be determined)
